SELUTION DeNovo Trial Substudy Compares SEB and DES in NSTEMI Patients

April 23, 2026—A substudy from the SELUTION DeNovo study analyzed 1,089 patients with non–ST-segment myocardial infarction (NSTEMI) or unstable angina to assess 1-year heart-related problems after treatment with either a drug-eluting stent (DES) or the Selution SLR sirolimus-eluting balloon (SEB; Cordis) with provisional stenting.

According to the Society for Cardiovascular Angiography & Interventions (SCAI), the SELUTION DeNovo prospective, randomized, open-label, multicenter, noninferiority trial compared the devices in an all-comers patient population. The findings were presented in a late-breaking clinical science session at SCAI 2026 in Montreal, Canada.

According to SCAI, the substudy’s findings support the use of SEB with minimal stenting as a safe and effective alternative to DES for patients with NSTEMI or unstable angina.

The SCAI press release reported the following low and similar findings for the SEB group versus the DES group:

• Target vessel failure, 5.3% versus 4.9%
• Cardiac death, 0.6% versus 0.8%
• Target-vessel–related myocardial infarction, 3.1% versus 2.8%
• Clinically driven target vessel revascularization, 3.1% versus 2.7%

“For many years, stents were the standard approach for these patients, but this study shows that we don’t always need to leave a permanent implant behind,” commented Christian Spaulding, MD, in the SCAI press release. “Using a selective drug-coated balloon strategy allows us to treat the blockage effectively while preserving the artery’s natural structure, giving clinicians more flexibility for future treatments.”